Latest News & Upcoming Events
“Go Big or Go Home” When Investing in Advanced Instrumentation
Due to the impact of AMD on several of his family members, Gary Kirman, OD (of Kirman Eye), has been a staunch advocate of dark adaptation testing as standard of care in eye care practices.
Read ArticleIdentify AMD Early to Reduce Risks
For patients who have early AMD and for those who have disease risk factors, patient compliance to prescribed treatments, early detection, and keeping a watchful eye on disease progression is key.
Read ArticleBig Change is a Small Choice
Just by adding dark adaptation testing to your practice, doctors can do more for patients at risk of developing AMD. By Julie Rodman, OD, MSc, FAAO.
Read ArticleAdaptDx Pro by MacuLogix Has Received a Medical Device License by Health Canada
The next generation of dark adaptation testing features a wearable headset and an artificial intelligence-driven onboard technician.
Read ArticleAdaptDx Pro Headset Set for Australian Debut
The AdaptDx Pro by MacuLogix launches in Australia, distributed by Optos and pending Therapeutic Goods Administration approval.
Read ArticleUpdates Come in Threes
Paul M. Karpecki, OD, dives into the replacement of oft-disliked tests with upgraded options that benefit patients and staff.
Read ArticleAMD: An Evolving Area of Revenue Growth in Optometric Practice
Craig Bowen, OD, (owner of Tualatin Eye Associates) discusses how change is often necessary in order to grow one’s practice.
Read ArticleThe Evolving Standard of Care in AMD
Leo Semes, OD, FAAO, Professor of Optometry at the University of Alabama-Birmingham, applies lessons learned from the treatment of glaucoma to the management of age-related macular degeneration.
Read Article‘Most Significant’ Eye Care Innovation…
The AdaptDx Pro may look like a pair of virtual reality goggles, but it’s really a device used for catching the early warning signs of age-related macular degeneration (AMD).
Read ArticleTurning Losses Into Gains
Leslie Gallagher, OD, FAAO, of Holton, Kansas discusses how a confirmed diagnosis of early or subclinical AMD provides her with the opportunity to discuss optical and nutraceutical needs, which benefit the patient and leads to additional revenue.
Read Article